Alzey Danışmanlık ve Ticaret Ltd. Şti. · İstanbul
Most distributors put your product on a shelf. We build the market that pulls it off.
We hold the licence, run the operation, and grow the accounts that sell your product — across Türkiye, the Caucasus and Central Asia, where the pathway is the product.
A standard distribution agreement covers three things: importing the product, warehousing it and delivering it when orders come in. In this region that is the easy part. Before a device sells here, someone has to hold the licence, train the physicians, build the demand and manage the receivables; a shelf-only distributor leaves most of that work on your side of the agreement, and you usually discover it only after the product is registered, stocked and not moving.
We close that gap under one agreement. The licence sits in our name, import and stock run on our books, the clinic network that sells your product is managed by our own field team, and the credit risk stays with us. That changes the incentive structure: if the product doesn’t move, we carry that outcome too, so leaving a report on the table and walking away is not an option we have.
We run the clinic network on the B2B side and patient demand on the B2C side. Both sit inside the same operation, so all three parties gain from the same transaction.
Sells into a channel that holds the licence, carries the stock and answers as one counterparty.
Finds the patients for the device without having to build the demand on its own.
Reaches treatment at the authorised centre that delivers it.
The step-by-step version, from licence to collections, sits on the medical operation page.
We open the pathway.
Registration files run in our name, from the TİTCK licence and ÜTS record in Türkiye to the active markets in Kazakhstan, Georgia and Azerbaijan. You supply the technical documentation; the filing, the follow-up and the outcome sit with us.
Not “we advise you on registration” — the dossier is ours.
We run it.
Import, customs, stock, field, receivables. We carry the credit.
We take the product from EXW, clear it through customs and hold buffer stock in our own warehouse, so an authorised centre never runs out. Channel credit risk sits with us, not with you: you deal with one counterparty, and collections in the field are our problem.
If the product isn’t moving, it’s our problem before it’s yours.
The part distributors skip.
We lower the clinic’s patient-acquisition cost through our own demand channel, clinic-level digital marketing and conversion optimisation, and we model the ROI on the clinic’s own numbers, not ours.
The patient-facing surfaces, the ad accounts and the CRM sit in-house and are run by our own team. The infrastructure is built; the organic engine isn’t fully running yet, and we’d rather say so here than have you find out later.
We don’t wait for the market. We build it.
No client names. Every line below carries a date and a document behind it.
What “100+ centres” counts: clinics, hospitals, obesity centres, medical-travel agencies and physician practices.
We don’t sell market-entry reports. If you want a deck, hire a consultancy.
Regulatory status may change; consult official TİTCK and FDA records for the current position.
Ventures: the same operating muscle, applied to F&B brands. For brand partners and investors.
Ventures →Everything above traces back to a signed agreement or a dated record. A first conversation covers your regulatory position, the commercial model and a realistic timeline, and if we’re not the right partner for your product, you’ll hear that in the same meeting.
